Broth microdilution protocol for determining antimicrobial susceptibility of Legionella pneumophila to clinically relevant antimicrobials

Currently there is no detailed, internationally agreed protocol defined to evaluate antimicrobial susceptibility testing (AST) for Legionella pneumophila (required to establish epidemiological cut-off value or "ECOFF" boundaries); therefore, antimicrobial resistance in these isolates cannot be defined. AST methods utilising media containing activated charcoal as an ingredient, to enable Legionella growth, are unreliable as noted in an internationally authored opinion paper and a new gold standard is required. Here we define a detailed protocol for broth microdilution (BMD) using defined cell culture collection-deposited control reference strains (Philadelphia-1 and Knoxville-1) as well as two accessible reference strains with moderately (lpeAB-carrying) and markedly (23S rRNA mutation-carrying) elevated azithromycin minimum inhibitory concentration (MIC). The defined protocol enables up to eight L. pneumophila strains to be set up on a single 96-well plate per antimicrobial tested. Initial ranges to routinely capture an MIC for these reference strains using clinically relevant antimicrobials azithromycin (0.01-0.25 mg/L), levofloxacin (0.008-0.03 mg/L), lefamulin (0.01-2 mg/L), rifampicin (0.0002-0.0008 mg/L) and doxycycline (0.25-16 mg/L) following incubation for 48 h at 37 °C in a shaking incubator have been empirically determined. Establishment of this internationally agreed protocol sets the scene for the next step: validation and comparison of antimicrobial ranges between international Legionella reference laboratories to establish putative resistance cut-off thresholds for these clinically relevant antimicrobials.

Authors

Institutions

Publication Details

Journal
Journal of Microbiological Methods
Published
2024-12-18
DOI
https://doi.org/10.1016/j.mimet.2024.107071
Citations
9
Primary Topic
Legionella and Acanthamoeba research
Type
article
Field-Weighted Citation Impact
5.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Broth microdilution protocol for determining antimicrobial susceptibility of Legionella pneumophila to clinically relevant antimicrobials

Fernando González‐Camacho, Søren Anker Uldum, Charlotte Michel, M. Mentasti et al.
9 citations
Journal of Microbiological Methods
Legionella and Acanthamoeba research
5.56
article

Broth microdilution protocol for determining antimicrobial susceptibility of Legionella pneumophila to clinically relevant antimicrobials

Fernando González‐Camacho, Søren Anker Uldum, Charlotte Michel, M. Mentasti, Ghislaine Descours, Juana María González-Rubio, Mandy Wooton, Baharak Afshar, Jonas M. Winchell, Lucy C. Jones, Caitlin Farley, Christophe Ginévra, Kathryn Bernard, Darja Keše, Edward Portal, Maria Scaturro, Diane Lindsay, Jacob Moran‐Gilad, Victoria J. Chalker, Anne Vatland Krøvel, Markus Petzold, Susanne Paukner, Sophie Jarraud, Rachael Barton, Ingrid Wybo, Anastasia Flountzi, O. Brad Spiller, Roisin Ure, Ian Boostom, Fedoua Echahdi, Sendurann Nadarajah, Valeria Gaia, Maria Luisa Ricci, Matej Golob, Max Sewell
article en
9 citations

Abstract

Currently there is no detailed, internationally agreed protocol defined to evaluate antimicrobial susceptibility testing (AST) for Legionella pneumophila (required to establish epidemiological cut-off value or "ECOFF" boundaries); therefore, antimicrobial resistance in these isolates cannot be defined. AST methods utilising media containing activated charcoal as an ingredient, to enable Legionella growth, are unreliable as noted in an internationally authored opinion paper and a new gold standard is required. Here we define a detailed protocol for broth microdilution (BMD) using defined cell culture collection-deposited control reference strains (Philadelphia-1 and Knoxville-1) as well as two accessible reference strains with moderately (lpeAB-carrying) and markedly (23S rRNA mutation-carrying) elevated azithromycin minimum inhibitory concentration (MIC). The defined protocol enables up to eight L. pneumophila strains to be set up on a single 96-well plate per antimicrobial tested. Initial ranges to routinely capture an MIC for these reference strains using clinically relevant antimicrobials azithromycin (0.01-0.25 mg/L), levofloxacin (0.008-0.03 mg/L), lefamulin (0.01-2 mg/L), rifampicin (0.0002-0.0008 mg/L) and doxycycline (0.25-16 mg/L) following incubation for 48 h at 37 °C in a shaking incubator have been empirically determined. Establishment of this internationally agreed protocol sets the scene for the next step: validation and comparison of antimicrobial ranges between international Legionella reference laboratories to establish putative resistance cut-off thresholds for these clinically relevant antimicrobials.

Journal of Microbiological MethodsVol. 228
Statens Serum Institut (DK), Ben-Gurion University of the Negev (IL), University of Ljubljana (SI), Glasgow Royal Infirmary (GB), University Hospital of Wales (GB), Public Health Wales (GB), Nabriva Therapeutics (Austria) (AT)
Cardiff University, European Society of Clinical Microbiology and Infectious Diseases
Zero hunger
Openalex Percentile: Top 4%
Legionella and Acanthamoeba research
5.56
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.